Shares of Qiagen have rebounded after three years following a news report that the provider of biotech workflow solutions was evaluating strategic options, which include a potential sale.
Probius to develop AI-powered point-of-care screening technology, eliminating sample preparation requirements and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results